Liver-Targeted siRNA Lipid Nanoparticles Treat Hepatic Cirrhosis by Dual Antifibrotic and Anti-inflammatory Activities

• Published in: ACS nano Vol. 14; no. 5; pp. 6305 - 6322
• Main Authors: Zhang, Jinfang, Shen, Hongwei, Xu, Jiaojiao, Liu, Li, Tan, Jingwen, Li, Minghao, Xu, Nan, Luo, Shenggen, Wang, Jing, Yang, Fan, Tang, Jie, Li, Qinghua, Wang, Yiting, Yu, Lei, Yan, Zhiqiang
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 26.05.2020
• Subjects: Animals; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; Hepatic Stellate Cells - pathology; Lipids; Liver Cirrhosis - drug therapy; Liver Cirrhosis - pathology; Mice; Nanoparticles; RNA, Small Interfering - genetics; RNA, Small Interfering - therapeutic use; hepatic cirrhosis; stable nucleic acid lipid nanoparticles (SNALPs); HMGB1-siRNA; liver fibrosis; liver inflammation; pPB peptide

Previous studies on the treatment of hepatic cirrhosis have been focusing on how to inhibit liver fibrosis, while ignoring liver inflammation, a key and underlying factor that promotes cirrhosis. High mobility group box-1 (HMGB1) protein, a pro-inflammatory factor and fibroblast chemokine, can promo...